Nature Medicine
This journal encompasses original research ranging from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative technologies aimed at improving human health.
We Need More Realistic Benchmarks for AI Models in Medicine
Large Language Models have shown impressive capabilities, but their medical knowledge has so far only been tested on medical licensing exams. We find that on more realistic tasks, such as clinical decision making, they lag behind medical experts, highlighting the need for more realistic benchmarks.
Omomyc is finally in the clinic. What a journey!
MYC is the most deregulated oncogene in human cancer, where it directs transcriptional programs that allow cancer cells to thrive and survive therapies. Despite being a most wanted target in cancer treatment, it has been long considered undruggable.
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection – the Antibody Mediated Prevention (AMP) trials
A new biomarker appears to be an effective surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium
Multiple non-endemic countries were recently hit by a monkeypox virus outbreak. While most cases present with lesions in the anogenital region, it is unclear whether asymptomatic or otherwise undiagnosed infections are fuelling this epidemic.
Composition of the gut microbiome is associated with response and toxicity following anti-CD19 CAR T cell therapy
The intestinal microbiome is associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B-cell malignancies.
When your body attacks itself – BTK inhibition shows promise for the treatment of chronic spontaneous urticaria (an autoimmune disease)
In a recent clinical trial, patients who had chronic spontaneous urticaria (CSU) for more than 6 months that would not respond to high doses of standard treatment (H1-antihistamines) – were enrolled to evaluate a “BTK blocker” drug, called, "fenebrutinib".
